TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18694217

Group type: EXPERIMENTAL
Intervention: Web-based portfolio system for feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (traditional feedback methods)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based portfolio system
Number of subjects: 0
Study: 15722818

Group type: EXPERIMENTAL
Intervention: FDG-PET imaging in patients with COPD
Number of subjects: 50

Group type: COMPARATOR
Intervention: FDG-PET imaging in patients without COPD
Number of subjects: 50
Study: 12150684

Group type: EXPERIMENTAL
Intervention: Broad-spectrum antifungal agents (new agents with enhanced activity against non-C. albicans and Aspergillus species)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reformulated older broad-spectrum antifungals
Number of subjects: 0
Study: 9485122

Group type: EXPERIMENTAL
Intervention: Noncoronary atherosclerosis (defined as claudication, peripheral vascular surgery, abdominal aortic aneurysm, history of cerebral ischemia, or carotid disease)
Number of subjects: 1816

Group type: COMPARATOR
Intervention: No noncoronary atherosclerosis
Number of subjects: 1816

Group type: EXPERIMENTAL
Intervention: Noncoronary atherosclerosis (surgery)
Number of subjects: 1816

Group type: EXPERIMENTAL
Intervention: Noncoronary atherosclerosis (angioplasty)
Number of subjects: 1816
Study: 7610928

Group type: EXPERIMENTAL
Intervention: Exercise program (aerobics and weight training)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Calcium supplementation
Number of subjects: 127
Study: 2201960

Group type: EXPERIMENTAL
Intervention: Theophylline (15-20 mg/L)
Number of subjects: 0
Study: 835370

Group type: EXPERIMENTAL
Intervention: Single oral dose of 6-propylthiouracil (PTU) in a fasting state
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Single oral dose of 6-propylthiouracil (PTU) with a standardized breakfast
Number of subjects: 8
Study: 30909946

Group type: EXPERIMENTAL
Intervention: Starting antiplatelet therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Avoiding antiplatelet therapy
Number of subjects: 0
Study: 28049624

Group type: EXPERIMENTAL
Intervention: Web 2.0 intervention
Number of subjects: 504

Group type: COMPARATOR
Intervention: Web 1.0 intervention
Number of subjects: 504

Group type: COMPARATOR
Intervention: Logbook intervention
Number of subjects: 504
Study: 25973670

Group type: EXPERIMENTAL
Intervention: Flow incentive spirometry
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Deep breathing
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Volume incentive spirometry
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control
Number of subjects: 137
Study: 23578454

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 120
Study: 20689306

Group type: EXPERIMENTAL
Intervention: Increased vocal intensity in non-cleft group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lowered pitch level
Number of subjects: 0
Study: 19054187

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including pain assessment at rest and with physical therapy, physician protocols for standing analgesia and preemptive analgesia before PT.
Number of subjects: 249

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 249
Study: 17089080

Group type: EXPERIMENTAL
Intervention: Balance Training Program
Number of subjects: 66
Study: 14718877

Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC (resin-modified glass ionomer cement)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Concise (composite resin, control group)
Number of subjects: 14
Study: 11354236

Group type: EXPERIMENTAL
Intervention: Milnacipran 50 mg b.d. for 6 weeks
Number of subjects: 113

Group type: COMPARATOR
Intervention: Fluvoxamine 100 mg b.d. for 6 weeks
Number of subjects: 113
Study: 9816524

Group type: EXPERIMENTAL
Intervention: Low activity 32P Palmaz-Schatz and BX radioactive stents
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 170
Study: 8549036

Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg once daily for 5 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2107653

Group type: EXPERIMENTAL
Intervention: GHRH (1‐29) NH2, 100 micrograms plus cortisone acetate 25 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GHRH (1‐29) NH2, 100 micrograms plus cortisone acetate 50 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: GHRH (1‐29) NH2, 100 micrograms
Number of subjects: 6
Study: 7358942

Group type: EXPERIMENTAL
Intervention: 1 mg lodoxamide ethyl
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3 mg lodoxamide ethyl
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31152534

Group type: EXPERIMENTAL
Intervention: Vortex massage procedures and controlled physical training (10 sessions)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Individually selected training (control group)
Number of subjects: 50
Study: 27198588

Group type: EXPERIMENTAL
Intervention: Minimally invasive (MI) flapless approach
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flapped surgery (FS)
Number of subjects: 40
Study: 25911562

Group type: EXPERIMENTAL
Intervention: Loxoprofen sodium (180 mg/day)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Celecoxib (200 mg/day)
Number of subjects: 141
Study: 23618777

Group type: EXPERIMENTAL
Intervention: Terlipressin infusion (3 μg kg(‐1) h(‐1) reduced to 1.5 μg kg(‐1) h(‐1) after reperfusion for 3 postoperative days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Terlipressin infusion
Number of subjects: 80
Study: 21244548

Group type: EXPERIMENTAL
Intervention: Caffeine citrate 20 mg/kg/day
Number of subjects: 287

Group type: COMPARATOR
Intervention: Caffeine citrate 5 mg/kg/day
Number of subjects: 287
Study: 19546455

Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention (60 minutes of bedside counselling, take-home materials, and 7 nurse-initiated counselling calls for 2 months after discharge)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Minimal smoking cessation intervention (advice from physicians and nurses and 2 pamphlets)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention
Number of subjects: 276

Group type: COMPARATOR
Intervention: Minimal smoking cessation intervention
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Patients admitted for CABG
Number of subjects: 276
Study: 17693684

Group type: EXPERIMENTAL
Intervention: Intramuscular iron injections
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 16
Study: 15013506

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in subthalamic nucleus (STN)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in globus pallidus internus (GPi)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Levodopa treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (age-matched subjects)
Number of subjects: 19
Study: 11776302

Group type: EXPERIMENTAL
Intervention: Dalteparin 5,000 IU anti‐Xa once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enoxaparin 4,000 IU anti‐Xa once daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tinzaparin 50 IU/kg anti‐Xa (average dose 3,650 anti‐Xa units) once daily
Number of subjects: 30
Study: 8827777

Group type: EXPERIMENTAL
Intervention: Cow's milk-based formula
Number of subjects: 20

Group type: COMPARATOR
Intervention: Casein hydrolysate formula
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both formulas
Number of subjects: 20
Study: 1593356

Group type: EXPERIMENTAL
Intervention: Colloidal volumes during the first 4 days of life (NICU 1)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Colloidal volumes during the first 4 days of life (NICU 3)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Signs of patent ductus arteriosus (NICU 1)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Signs of patent ductus arteriosus (NICU 2)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Signs of patent ductus arteriosus (NICU 3)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Maximum inspired oxygen fraction during the first 4 days
Number of subjects: 223

Group type: COMPARATOR
Intervention: Maximum arterial oxygen tension (NICU 3)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Positive end‐expiratory pressure
Number of subjects: 223
Study: 6239670

Group type: EXPERIMENTAL
Intervention: Applied relaxation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Applied relaxation plus operant conditioning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment groups (applied relaxation and applied relaxation plus operant conditioning)
Number of subjects: 0
Study: 30260488

Group type: EXPERIMENTAL
Intervention: Experimental very high-protein (37%) and low-carbohydrate (29%) EN formula
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control high-protein (25%) and conventional-carbohydrate (45%) EN formula
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Experimental very high-protein and low-carbohydrate EN formula
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control high-protein and conventional-carbohydrate EN formula
Number of subjects: 105
Study: 29249371

Group type: EXPERIMENTAL
Intervention: 1 Hz-rTMS to right dlPFC
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sham stimulation to right dlPFC
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 1 Hz-rTMS to left dlPFC
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 1 Hz-rTMS to left dlPFC in older adults
Number of subjects: 71
Study: 27055275

Group type: EXPERIMENTAL
Intervention: Test-based approach using RDTs (RDT arm)
Number of subjects: 3046

Group type: COMPARATOR
Intervention: Presumptive approach using clinical judgment (CJ arm)
Number of subjects: 3046
Study: 24912736

Group type: EXPERIMENTAL
Intervention: Stress management program (education on diet and exercise, stress coping methods, relaxation breathing, and progressive muscle relaxation)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Waitlist control group (no additional intervention)
Number of subjects: 22
Study: 22513288

Group type: EXPERIMENTAL
Intervention: Luminal A breast cancer
Number of subjects: 281

Group type: COMPARATOR
Intervention: Core basal phenotype (CBP) breast cancer
Number of subjects: 281
Study: 20044806

Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 1347

Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 1347
Study: 16864983

Group type: COMPARATOR
Intervention: Conjugated estrogens (Premarin 0.625 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tibolone (Livial 2.5 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (normal menstrual cycles)
Number of subjects: 30
Study: 16244510

Group type: EXPERIMENTAL
Intervention: 1-year lifestyle/stress management program (n = 48)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Written advice (n = 53)
Number of subjects: 101
Study: 12403882

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 12
Study: 10025391

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 54
Study: 8804470

Group type: COMPARATOR
Intervention: PNC + PLC (Placebo)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PNC + DXM (Dexamethasone)
Number of subjects: 80
Study: 1777550

Group type: EXPERIMENTAL
Intervention: Yohimbine (15 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Ephedrine (50 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 6127224

Group type: EXPERIMENTAL
Intervention: Dynorphin‐(1‐13) at a dose of 60 micrograms/kg body weight
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 12
Study: 31219276

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance at Session 3, 4, or 5
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Between-therapist effect of the alliance
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Within-therapist (client) effect of the alliance
Number of subjects: 144
Study: 28974553

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of allogenic UC‐MSCs (1×10^6 cells/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of allogenic UC‐MSCs
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 26335982

Group type: EXPERIMENTAL
Intervention: EHR-acknowledged alerts
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: ANCR-acknowledged alerts
Number of subjects: 171

Group type: COMPARATOR
Intervention: Preintervention alerts
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Postintervention alerts
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Postintervention EHR alerts
Number of subjects: 171
Study: 24491609

Group type: EXPERIMENTAL
Intervention: Shared decision-making intervention (n=13)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual care condition (n=14)
Number of subjects: 27
Study: 21837450

Group type: EXPERIMENTAL
Intervention: Plyometric exercise (PL group, n = 8)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intermittent running (IR group, n = 8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sedentary control (CON group, n = 8)
Number of subjects: 24
Study: 19942724

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 26

Group type: COMPARATOR
Intervention: Local anaesthetic injection
Number of subjects: 26
Study: 17470161

Group type: EXPERIMENTAL
Intervention: Monthly i.v. clodronate
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Monthly i.v. zoledronic acid
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 94
Study: 15141904

Group type: EXPERIMENTAL
Intervention: Cup stacking program (5 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study: 11234138

Group type: EXPERIMENTAL
Intervention: Carvedilol (14 patients)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Atenolol (14 patients)
Number of subjects: 28
Study: 9487210

Group type: EXPERIMENTAL
Intervention: Valacyclovir (1000 mg twice daily for 5 days)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Acyclovir (200 mg 5 times daily for 5 days)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study: 8045141

Group type: EXPERIMENTAL
Intervention: HA-1A (100 mg)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 543
Study: 3059756

Group type: EXPERIMENTAL
Intervention: 75 mg of acetaminophen
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study: 30442653

Group type: EXPERIMENTAL
Intervention: Oral pregabalin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 0
Study: 28196711

Group type: EXPERIMENTAL
Intervention: Cognitive defusion
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 191

Group type: COMPARATOR
Intervention: Mind-wandering (control)
Number of subjects: 191
Study: 25420129

Group type: EXPERIMENTAL
Intervention: Integrated adventure-based training and health education program
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 69
Study: 22269473

Group type: EXPERIMENTAL
Intervention: 10mg mifepristone daily for 6 months
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 5mg mifepristone daily for 6 months
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Post-treatment follow-up at 12 months
Number of subjects: 176
Study: 19895922

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Number of subjects: 619

Group type: COMPARATOR
Intervention: MPSV4
Number of subjects: 619
Study: 18035001

Group type: EXPERIMENTAL
Intervention: Chlorogenic acid enriched instant coffee
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal instant coffee
Number of subjects: 42
Study: 15663703

Group type: EXPERIMENTAL
Intervention: Specialty care payment carve-out from Medicaid managed care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Children in managed care counties who were not mandated to enroll
Number of subjects: 0

Group type: COMPARATOR
Intervention: Children in nonmanaged care counties
Number of subjects: 0
Study: 12085142

Group type: EXPERIMENTAL
Intervention: Laparoscopic Colon Resection (LCR)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Open Colon Resection (OCR)
Number of subjects: 83
Study: 10432409

Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 262

Group type: COMPARATOR
Intervention: Sandimmune
Number of subjects: 262
Study: 7541235

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with PBPC support and G-CSF (12 or 30 micrograms kg‐1 day‐1 for 10 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with PBPC support and G-CSF
Number of subjects: 10
Study: 2386358

Group type: EXPERIMENTAL
Intervention: Continuous interscalene brachial plexus block with 0.75% bupivacaine (150‐210 mg) with adrenaline, followed by an infusion of 0.25% bupivacaine 0.25 mg/kg/h
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anaesthesia after starting a continuous interscalene brachial plexus block with a test dose of 0.75% bupivacaine (22.5 mg) with adrenaline, followed by an infusion of 0.25% bupivacaine 0.25 mg/kg/h
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Continuous interscalene brachial plexus block
Number of subjects: 40
Study: 514425

Group type: EXPERIMENTAL
Intervention: Glucose-enriched dialysate (400 mg/100 ml)
Number of subjects: 10
Study: 31263024

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with bevacizumab (15 mg/kg every 3 weeks for ≥3 cycles)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy alone
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with bevacizumab
Number of subjects: 68
Study: 30293817

Group type: EXPERIMENTAL
Intervention: Dequalinium chloride
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Clofoctol
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Dequalinium chloride and Clofoctol
Number of subjects: 1
Study: 26270693

Group type: EXPERIMENTAL
Intervention: Nucleotide supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24682080

Group type: EXPERIMENTAL
Intervention: Continuous sciatic nerve block (0.2% ropivacaine 5 mL/h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single-injection sciatic nerve block (0.2% ropivacaine 20 mL) with sham continuous SNB (0.9% normal saline 5 mL/h)
Number of subjects: 60
Study: 22467087

Group type: COMPARATOR
Intervention: Local steroid injection
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Surgical decompression
Number of subjects: 163
Study: 20955868

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 19020138

Group type: EXPERIMENTAL
Intervention: Blanket method
Number of subjects: 85

Group type: COMPARATOR
Intervention: Table-ramp method
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study: 15943172

Group type: EXPERIMENTAL
Intervention: Cognitive group treatment program (10-week, 30 hours)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Comparison of treatment vs control at 18 months
Number of subjects: 105
Study: 11898037

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (5‐fluorouracil + cisplatin) with concomitant 45 Gray radiotherapy in a 5‐week course
Number of subjects: 61

Group type: COMPARATOR
Intervention: Surgery alone (standard surgical group)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Pathologic complete response (pCR) group
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Pathologic incomplete response (pIR) group
Number of subjects: 61
Study: 10395845

Group type: EXPERIMENTAL
Intervention: Current standard therapy (2 nucleoside analogues and a protease inhibitor)
Number of subjects: 16
Study: 7477616

Group type: EXPERIMENTAL
Intervention: Diabetic gastroparesis (DGP) group
Number of subjects: 226
Study: 2182236

Group type: EXPERIMENTAL
Intervention: Anistreplase (30 U administered intravenously within the first 6 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7372824

Group type: EXPERIMENTAL
Intervention: Auditory biofeedback of digital skin temperature (DST) during Increase trials
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Auditory biofeedback of digital skin temperature (DST) during Decrease trials
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline trials (no feedback)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Decrease trials
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Increase trials
Number of subjects: 10
Study: 31472691

Group type: EXPERIMENTAL
Intervention: Percutaneous minimally invasive approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional open approach
Number of subjects: 0
Study: 28472499

Group type: EXPERIMENTAL
Intervention: Pharmacy Management Service (PharMS)
Number of subjects: 157
Study: 27199158

Group type: EXPERIMENTAL
Intervention: Whole grain bread
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional bread
Number of subjects: 11
Study: 23432528

Group type: EXPERIMENTAL
Intervention: Romiplostim (mean 5-8 μg/kg, self-administered at home)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 292
Study: 21347869

Group type: EXPERIMENTAL
Intervention: High-dose selenium supplementation (Se+ group, n = 75) - 1,000 μg on day 1, 500 μg/day on days 2-14
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard selenium dose (<75 μg/day) in control group (Se- group, n = 75)
Number of subjects: 150
Study: 19527280

Group type: EXPERIMENTAL
Intervention: Nebulized fentanyl (NF) at 4 microg/kg
Number of subjects: 77

Group type: COMPARATOR
Intervention: Intravenous morphine (IVM) at 0.1 mg/kg
Number of subjects: 77
Study: 18642378

Group type: EXPERIMENTAL
Intervention: Diathermy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham-diathermy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control
Number of subjects: 35